NeuroHealing Announces Treatment of First Patient in NH004 Parkinson’s Clinical Trial
Newton, Massachusetts, May 6, 2013. NeuroHealing Pharmaceuticals Inc., a private, clinical stage company announced today the treatment of the first patient in a Phase II study to test the efficacy of NH004 in reducing the symptom of sialorrhea (drooling) in Parkinson’s disease patients. NH004 is a novel slow dissolving intra-oral muco-adhesive thin film containing the…